Soft tissue sarcoma therapy widens around fusion-defined biomarkers
NTRK inhibitor cross-tumour use, GIST line-of-therapy expansion, and emerging mechanism-targeted programs are reshaping soft tissue sarcoma management.
Soft tissue sarcoma has been a histology-and-doxorubicin-based-chemotherapy category for years. NTRK inhibitors (larotrectinib, entrectinib) carry tumour-agnostic approval and are routinely used in NTRK-fusion-positive sarcomas, GIST line-of-therapy has widened (imatinib, sunitinib, regorafenib, ripretinib, avapritinib in PDGFRA D842V mutation), and emerging mechanism-targeted programs across specific sarcoma subtypes are reading out. The biomarker-pathway and pathology-review-quality question shapes commercial reach.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
Related
- SnapshotAdult diffuse glioma therapy reference (2026)
- ExplainedWhat is glioblastoma?